165 related articles for article (PubMed ID: 30092742)
1. Potential role of rituximab in metastatic castrate-resistant prostate cancer.
Bindal P; Jalil SA; Holle LM; Clement JM
J Oncol Pharm Pract; 2019 Sep; 25(6):1509-1511. PubMed ID: 30092742
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
3. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
4. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
Cabel L; Loir E; Gravis G; Lavaud P; Massard C; Albiges L; Baciarello G; Loriot Y; Fizazi K
J Immunother Cancer; 2017; 5():31. PubMed ID: 28428880
[TBL] [Abstract][Full Text] [Related]
5. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S
J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297
[TBL] [Abstract][Full Text] [Related]
6. Management of castrate-resistant prostate cancer in older men.
Ged Y; Horgan AM
J Geriatr Oncol; 2016 Mar; 7(2):57-63. PubMed ID: 26907565
[TBL] [Abstract][Full Text] [Related]
7. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
Küronya Z; Bíró K; Gyergyay F; Géczi L
Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
[TBL] [Abstract][Full Text] [Related]
8. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
Hauke R
Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
11. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
12. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
13. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Westaby D; Viscuse PV; Ravilla R; de la Maza MLDF; Hahn A; Sharp A; de Bono J; Aparicio A; Fleming MT
Am Soc Clin Oncol Educ Book; 2021 Jun; 41():e190-e202. PubMed ID: 34061561
[TBL] [Abstract][Full Text] [Related]
14. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
15. Optimal Management of Prostate Cancer Based on its Natural Clinical History.
Facchini G; Perri F; Misso G; D'Aniello C; Scarpati GDV; Rossetti S; Pepa CD; Pisconti S; Unteregger G; Cossu A; Caraglia M; Berretta M; Cavaliere C
Curr Cancer Drug Targets; 2018; 18(5):457-467. PubMed ID: 28183253
[TBL] [Abstract][Full Text] [Related]
16. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
Shiota M; Eto M
Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
[TBL] [Abstract][Full Text] [Related]
17. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Hussain A; Tripathi A; Pieczonka C; Cope D; McNatty A; Logothetis C; Guise T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):290-300. PubMed ID: 33028943
[TBL] [Abstract][Full Text] [Related]
18. Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
Porter LH; Hashimoto K; Lawrence MG; Pezaro C; Clouston D; Wang H; Papargiris M; Thorne H; Li J; ; Ryan A; Norden S; Moon D; Bolton DM; Sengupta S; Frydenberg M; Murphy DG; Risbridger GP; Taylor RA
BJU Int; 2018 Jun; 121(6):971-978. PubMed ID: 28977728
[TBL] [Abstract][Full Text] [Related]
19. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
20. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
